This is a relatively New Company
This is a Relatively New DRUG
It was JUST Approved
It saves lives
Lt reduces Infections
It reduce re-occurrences of infections
Many Biotechs have no Approved Products
Many Biotechs are borrowing everyday to stay Afloat
There are many Large Pharmas that would love to add this product to their portfolio
After a Full Quarter of Sales and more approvals in other regions of the world, the Upside is ENORMOUS
This drug WORKS MUCH better than the competition...That is the most Important thing to consider
Now Someone with any level of intelligence tell me anything negative
While I am long and have high hopes for optimer I still have to ask--
IF big pharma wants to buy where are the offers. Trials are done,we have approval.
Why would yell MUCH BETTER than the competition? Better yes but not tremendously so.
Other than that I more or less agree.
offers tend to come during hard times, don't they, like when a stock has been pushed down after earnings without equivalent justification?
If there's going to be a buy-out offer, it'll come this weekend (if OPTR is still down by 11%). If not then, it will not come.
Like the subject line says...missing the point....my mom contracted c-dif in the hospital...re-hospitalized 3 times....weakened her and created a Vancomycin resistance...she didnt recover enough after surgery...at least partially due to c-dif...took her to Hospice yesterday.....it's not a little better...it's quite a bit better...go to your local hospital and count the quarantine gown carts in the halls...now go to hospice and ask those affected if they wish that a drug thats better had been tried.....now...you get the point!!!!
This is a relatively New Company (yes and management and BOD and horrible)
This is a Relatively New DRUG (yes, with no long-term composition of matter protection)
It was JUST Approved (big deal, look at AMAG or DNDN for comparison of overbloated/hyped expectations)
It saves lives (comprabable to oral Vanc)
Lt reduces Infections (comprabable to oral Vanc)
It reduce re-occurrences of infections (marginally, not worth the extra cost when generic Vanc makers hit the market...will be soon in the making!)
Many Biotechs have no Approved Products (yes, but some do. Most have horrible management and cost/expense structures....OPTR has ~10VPs all making >$350K/year plus bonuses plus stock, which retail investors pay for)
Many Biotechs are borrowing everyday to stay Afloat (yes, and this one will borrow as well as revenues can not keep up with expenses...rest assured there will be addtional offerings as well to dilute retail investors!)
There are many Large Pharmas that would love to add this product to their portfolio (NOPE! Patent life not good enough. And best case scenario for commercial models are ~$200-250 Million/year...best case peak sales, but will never get there in my opinion)
After a Full Quarter of Sales and more approvals in other regions of the world, the Upside is ENORMOUS (US will be there best market hands down, so added revenue from other markets are marginal)
This drug WORKS MUCH better than the competition...That is the most Important thing to consider (NOPE, comprabable to Vanc, slight improvement in recurrence)
You are so right!!!!!!!!!! told Mike we would have a chance to add shares at low to mid $14'S..NEVER THOUGHT i WOULD SEE 13...BUT HERE IT IS!!! I plan to add big tmrw. I will wait to see if the uneducated take it lower.. I cannot believe that the shorts don't do DD...as this is very new and the numbers are good for such a promising drug....What idiot did not think there would be launch expenses?? Remember..,every day the need for this drug grows because of Vanco re-admissions...